(VIANEWS) – 2020 BULKERS (2020.OL), IBA (IBAB.BR), SARTORIUS STED BIO (DIM.PA) are the highest payout ratio stocks on this list.
We have collected information regarding stocks with the highest payout ratio so far. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. 2020 BULKERS (2020.OL)
106.82% Payout Ratio
2020 Bulkers Ltd. owns and operates large dry bulk vessels worldwide. It operates eight scrubber fitted 208,000 deadweight tonnage Newcastlemax dry bulk vessels. 2020 Bulkers Ltd. was incorporated in 2017 and is based in Hamilton, Bermuda.
Earnings Per Share
As for profitability, 2020 BULKERS has a trailing twelve months EPS of kr24.75.
PE Ratio
2020 BULKERS has a trailing twelve months price to earnings ratio of 6.27. Meaning, the purchaser of the share is investing kr6.27 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.64%.
More news about 2020 BULKERS.
2. IBA (IBAB.BR)
94.67% Payout Ratio
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Earnings Per Share
As for profitability, IBA has a trailing twelve months EPS of €-0.31.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.2%.
Yearly Top and Bottom Value
IBA’s stock is valued at €13.60 at 12:10 EST, way below its 52-week high of €17.20 and way above its 52-week low of €8.26.
More news about IBA.
3. SARTORIUS STED BIO (DIM.PA)
42.86% Payout Ratio
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.15%.
More news about SARTORIUS STED BIO.
4. IRISH CONT. GP. (IR5B.IR)
40.11% Payout Ratio
Irish Continental Group plc operates as a maritime transport company. It operates through two segments, Ferries, and Container and Terminal. The Ferries segment provides ferry services carrying passengers and roll on roll off freight on short sea routes on routes between Ireland, Britain, and Continental Europe under the Irish ferries brand; and chartering services. The Container and Terminal segment provides door-to-door and feeder lift on lift off freight services under the Eucon brand, stevedoring, and other related terminal services, as well as operates container terminals in the ports of Dublin and Belfast. The company provides container shipping, ship leasing, administration, and container handling services. In addition, it operates ferry; and act as a shipping and forwarding agency; as well as is involved in non-trading activities. Irish Continental Group plc was founded in 1972 and is based in Dublin, Ireland.
Earnings Per Share
As for profitability, IRISH CONT. GP. has a trailing twelve months EPS of €0.36.
PE Ratio
IRISH CONT. GP. has a trailing twelve months price to earnings ratio of 16.22. Meaning, the purchaser of the share is investing €16.22 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.68%.
More news about IRISH CONT. GP..
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Volatility
1’s last week, last month’s, and last quarter’s current intraday variation average was 1.00%, 1.00%, and 1.00%.
1’s highest amplitude of average volatility was 1.00% (last week), 1.00% (last month), and 1.00% (last quarter).
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 1% and 1%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1%, now sitting on 1 for the twelve trailing months.
Volume
Today’s last reported volume for 1 is 1 which is 1% above its average volume of 1.
More news about 1.
